Details of Protein
| General Information of Protein (ID: PRT00067) | |||||
|---|---|---|---|---|---|
| Name | DAN domain family member 5 (DAND5) | ||||
| Synonyms |
Click to Show/Hide Synonyms of This Protein
Cerberus-like protein 2; Cerl-2; Cysteine knot superfamily 1, BMP antagonist 3; Gremlin-3; DAND5; CER2; CKTSF1B3; GREM3; SP1
|
||||
| Gene Name | DAND5 | Gene ID | |||
| UniProt ID | |||||
| Family | Bone morphogenic antagonist (BMA) | ||||
| Click to Show/Hide the Molecular/Functional Data (Sequence/Structure/Function) of This Protein | |||||
| Sequence |
MLLGQLSTLLCLLSGALPTGSGRPEPQSPRPQSWAAANQTWALGPGALPPLVPASALGSW
KAFLGLQKARQLGMGRLQRGQDEVAAVTLPLNPQEVIQGMCKAVPFVQVFSRPGCSAIRL RNHLCFGHCSSLYIPGSDPTPLVLCNSCMPARKRWAPVVLWCLTGSSASRRRVKISTMLI EGCHCSPKA |
||||
| Function | Seems to play a role in the correct specification of the left-right axis. May antagonize NODAL and BMP4 signaling. Cystine knot-containing proteins play important roles during development, organogenesis, tissue growth and differentiation. | ||||
| Regulatory Network | |||||
| Full List of Metabolite(s) Regulated by This Protein | ||||||
|---|---|---|---|---|---|---|
| Lipid-related molecules | ||||||
| C24:1-ceramide | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
| Detailed Information |
Metabo Info
click to show the details of this metabolite
|
|||||
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[1] | ||||
| Introduced Variation | Knockdown (siRNA) of DAND5 | |||||
| Induced Change | C24:1-ceramide concentration: decrease | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Healthy individual | |||||
| Details | It is reported that knockdown of DAND5 leads to the decrease of C24:1-ceramide levels compared with control group. | |||||
| Ceramide C18:1 | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
| Detailed Information |
Metabo Info
click to show the details of this metabolite
|
|||||
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[1] | ||||
| Introduced Variation | Knockdown (siRNA) of DAND5 | |||||
| Induced Change | Ceramide C18:1 concentration: increase | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Healthy individual | |||||
| Details | It is reported that knockdown of DAND5 leads to the increase of ceramide c18:1 levels compared with control group. | |||||
| Ceramide C24:1 | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
| Detailed Information |
Metabo Info
click to show the details of this metabolite
|
|||||
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[1] | ||||
| Introduced Variation | Knockdown (siRNA) of DAND5 | |||||
| Induced Change | Ceramide C24:1 concentration: increase | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Healthy individual | |||||
| Details | It is reported that knockdown of DAND5 leads to the increase of ceramide c24:1 levels compared with control group. | |||||
| Lipids and lipid-like molecules | ||||||
| Ceramide(d18:1/14:0) | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
| Detailed Information |
Metabo Info
click to show the details of this metabolite
|
|||||
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[1] | ||||
| Introduced Variation | Knockdown (siRNA) of DAND5 | |||||
| Induced Change | Ceramide(d18:1/14:0) concentration: decrease | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Healthy individual | |||||
| Details | It is reported that knockdown of DAND5 leads to the decrease of ceramide(d18:1/14:0) levels compared with control group. | |||||
| Ceramide(d18:1/16:0) | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
| Detailed Information |
Metabo Info
click to show the details of this metabolite
|
|||||
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[1] | ||||
| Introduced Variation | Knockdown (siRNA) of DAND5 | |||||
| Induced Change | Ceramide(d18:1/16:0) concentration: increase | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Healthy individual | |||||
| Details | It is reported that knockdown of DAND5 leads to the increase of ceramide(d18:1/16:0) levels compared with control group. | |||||
| Ceramide(d18:1/23:0) | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
| Detailed Information |
Metabo Info
click to show the details of this metabolite
|
|||||
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[1] | ||||
| Introduced Variation | Knockdown (siRNA) of DAND5 | |||||
| Induced Change | Ceramide(d18:1/23:0) concentration: increase | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Healthy individual | |||||
| Details | It is reported that knockdown of DAND5 leads to the increase of ceramide(d18:1/23:0) levels compared with control group. | |||||
| Ceramide(d18:1/24:0) | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
| Detailed Information |
Metabo Info
click to show the details of this metabolite
|
|||||
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[1] | ||||
| Introduced Variation | Knockdown (siRNA) of DAND5 | |||||
| Induced Change | Ceramide(d18:1/24:0) concentration: decrease | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Healthy individual | |||||
| Details | It is reported that knockdown of DAND5 leads to the decrease of ceramide(d18:1/24:0) levels compared with control group. | |||||
| CerP(d18:1/16:0) | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
| Detailed Information |
Metabo Info
click to show the details of this metabolite
|
|||||
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[1] | ||||
| Introduced Variation | Knockdown (siRNA) of DAND5 | |||||
| Induced Change | CerP(d18:1/16:0) concentration: decrease | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Healthy individual | |||||
| Details | It is reported that knockdown of DAND5 leads to the decrease of cerP(d18:1/16:0) levels compared with control group. | |||||
| GlcCer(d18:1/18:0) | Click to Show/Hide the Full List of Regulating Pair(s): 1 Pair(s) | |||||
| Detailed Information |
Metabo Info
click to show the details of this metabolite
|
|||||
| Regulating Pair |
Experim Info
click to show the details of experiment for validating this pair
|
[1] | ||||
| Introduced Variation | Knockdown (siRNA) of DAND5 | |||||
| Induced Change | GlcCer(d18:1/18:0) concentration: decrease | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Healthy individual | |||||
| Details | It is reported that knockdown of DAND5 leads to the decrease of glcCer(d18:1/18:0) levels compared with control group. | |||||
| Sphingosine 1-phosphate | Click to Show/Hide the Full List of Regulating Pair(s): 2 Pair(s) | |||||
| Detailed Information |
Metabo Info
click to show the details of this metabolite
|
|||||
| Regulating Pair (1) |
Experim Info
click to show the details of experiment for validating this pair
|
[1] | ||||
| Introduced Variation | Knockdown (siRNA) of DAND5 | |||||
| Induced Change | Sphingosine 1-phosphate concentration: decrease | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Healthy individual | |||||
| Details | It is reported that knockdown of DAND5 leads to the decrease of sphingosine 1-phosphate levels compared with control group. | |||||
| Regulating Pair (2) |
Experim Info
click to show the details of experiment for validating this pair
|
[1] | ||||
| Introduced Variation | Knockdown (siRNA) of DAND5 | |||||
| Induced Change | Sphingosine 1-phosphate concentration: increase (FC = 5.09) | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Healthy individual | |||||
| Details | It is reported that knockdown of DAND5 leads to the increase of sphingosine 1-phosphate levels compared with control group. | |||||
| Organic nitrogen compounds | ||||||
| Sphingosine | Click to Show/Hide the Full List of Regulating Pair(s): 2 Pair(s) | |||||
| Detailed Information |
Metabo Info
click to show the details of this metabolite
|
|||||
| Regulating Pair (1) |
Experim Info
click to show the details of experiment for validating this pair
|
[1] | ||||
| Introduced Variation | Knockdown (siRNA) of DAND5 | |||||
| Induced Change | Sphingosine concentration: decrease | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Healthy individual | |||||
| Details | It is reported that knockdown of DAND5 leads to the decrease of sphingosine levels compared with control group. | |||||
| Regulating Pair (2) |
Experim Info
click to show the details of experiment for validating this pair
|
[1] | ||||
| Introduced Variation | Knockdown (siRNA) of DAND5 | |||||
| Induced Change | Sphingosine concentration: increase (FC = 1.82) | |||||
| Summary | Introduced Variation
|
|||||
| Disease Status | Healthy individual | |||||
| Details | It is reported that knockdown of DAND5 leads to the increase of sphingosine levels compared with control group. | |||||
| References | |||||
|---|---|---|---|---|---|
| 1 | Golgi alkaline ceramidase regulates cell proliferation and survival by controlling levels of sphingosine and S1P. FASEB J. 2006 Sep;20(11):1813-25. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.

